Dr. Mark Payne, a professor of pediatrics at the Indiana University School of Medicine and a pediatric cardiologist at Riley ...
LX2006 (AAVrh.10hFXN) is an adeno-associated virus gene therapy candidate designed to deliver a functional frataxin gene to cardiac cells to improve mitochondrial function. The Food and Drug ...
Ataxia affects the nervous system, disrupting muscle control, coordination, and balance. It can be hereditary, acquired, or sporadic, with each type requiring different diagnostic methods and care ...
Ataxia is more than just clumsiness—it’s a neurological condition that affects coordination, balance, speech, and even vision ...
The firm will deliver SGT-212 to patients' brains and intravenously to try to restore frataxin levels and diminish ...
A key opinion leader examines the November 2022 guidelines for managing Friedreich's ataxia, discusses the first FDA-approved therapy for the condition, and explains how this treatment is integrated ...
Price negotiations for the Syclarys medication for the rare, neurodegenerative disease Friedrichs Ataxia (FA) are ongoing, ...
Please provide your email address to receive an email when new articles are posted on . Vatiquinone inhibits 15-Lipoxygenase, which regulates the pathways that Friedreich’s ataxia disrupts. PTC ...